Cite
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
MLA
Xu, Jie, et al. “Long-Term Remission and Survival in Patients with Relapsed or Refractory Multiple Myeloma after Treatment with LCAR-B38M CAR T Cells: 5-Year Follow-up of the LEGEND-2 Trial.” Journal of Hematology & Oncology, vol. 17, Apr. 2024, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s13045-024-01530-z.
APA
Xu, J., Wang, B.-Y., Yu, S.-H., Chen, S.-J., Yang, S.-S., Liu, R., Chen, L.-J., Hou, J., Chen, Z., Zhao, W.-H., He, A.-L., Mi, J.-Q., & Chen, S.-J. (2024). Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. Journal of Hematology & Oncology, 17, 1–13. https://doi.org/10.1186/s13045-024-01530-z
Chicago
Xu, Jie, Bai-Yan Wang, Shan-He Yu, Shi-Jun Chen, Shuang-Shuang Yang, Rui Liu, Li-Juan Chen, et al. 2024. “Long-Term Remission and Survival in Patients with Relapsed or Refractory Multiple Myeloma after Treatment with LCAR-B38M CAR T Cells: 5-Year Follow-up of the LEGEND-2 Trial.” Journal of Hematology & Oncology 17 (April): 1–13. doi:10.1186/s13045-024-01530-z.